Related Experiment Video

Updated: Feb 10, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.5K

Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment

Kazutoshi Sugiyama1, Yoshifumi Saisho2

  • 1Division of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. ksugiyama@keio.jp.

Diseases (Basel, Switzerland)
|May 26, 2018
PubMed

Insights

Dyslipidemia in type 2 diabetes poses cardiovascular risks. Nonstatin therapies like ezetimibe and PCSK9 inhibitors offer effective management for patients with residual risk or statin intolerance.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Dyslipidemia is a primary risk factor for cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM).
  • Statins are standard but leave residual risk and have a notable rate of intolerance (up to 20%), often presenting as muscle symptoms.

Purpose of the Study:

  • To review the role of nonstatin therapies in managing dyslipidemia in T2DM patients.
  • To discuss the benefits and safety of ezetimibe and PCSK9 monoclonal antibodies (mAbs).
  • To introduce emerging novel drugs for dyslipidemia management.

Main Methods:

  • Review of clinical trial data and scientific literature on nonstatin lipid-lowering agents.
  • Analysis of efficacy and safety profiles of ezetimibe and PCSK9 mAbs in cardiovascular outcome trials.
  • Summary of current evidence and future directions in T2DM dyslipidemia management.

Main Results:

  • Ezetimibe and PCSK9 mAbs demonstrate significant benefits in reducing cardiovascular events with favorable safety profiles.
  • These agents are effective for patients with statin intolerance or those not reaching LDL-C goals on statins.
  • Ongoing research is exploring novel therapeutic targets and agents.

Conclusions:

  • Nonstatin therapies, including ezetimibe and PCSK9 mAbs, are crucial in managing dyslipidemia and reducing cardiovascular risk in T2DM.
  • These agents offer valuable alternatives for patients with statin-related side effects or inadequate LDL-C reduction.
  • The landscape of dyslipidemia management in T2DM is expanding with promising new drug developments.
Keywords:
PCSK9dyslipidemianonstatintype 2 diabetes

More Related Videos

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.1K
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

6.2K

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques01:30

Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques

Airway management is essential in emergency and surgical medicine, ensuring ventilation and oxygenation in patients who cannot maintain their own airway. Clinicians use a range of techniques and devices to secure the airway, depending on the patient’s condition and the clinical context. Key methods include endotracheal intubation, rapid sequence intubation (RSI), supraglottic airway devices, and advanced visualization aids. In cases where these approaches fail, surgical airway...
592
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.7K
Overview of Advanced Functional Groups02:22

Overview of Advanced Functional Groups


Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
30.1K